Neptune Technologies & Bioressources Inc  

(Public, TSE:NTB)   Watch this stock  
Find more results for NTB
+0.08 (4.49%)
Oct 20 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.80 - 1.88
52 week 1.26 - 4.00
Open 1.80
Vol / Avg. 34,135.00/140,465.00
Mkt cap 137.25M
P/E     -
Div/yield     -
EPS -0.37
Shares 74.98M
Beta 1.66
Inst. own     -
Oct 15, 2014
Q2 2015 Neptune Technologies & Bioressources Inc Earnings Call
Oct 14, 2014
Q2 2015 Neptune Technologies & Bioressources Inc Earnings Release
Sep 10, 2014
Neptune Technologies & Bioressources Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q3 (Aug '14) 2014
Net profit margin -566.10% -114.06%
Operating margin -549.71% -112.41%
EBITD margin - -103.69%
Return on average assets -48.53% -26.21%
Return on average equity -70.05% -31.30%
Employees 111 -
CDP Score - -


Suite 200, 225 Promenade du Centropolis
+1-450-6872262 (Phone)
+1-450-6872272 (Fax)

Website links


Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune�s distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company�s products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).

Officers and directors

Pierre Fitzgibbon Chairman of the Board
Age: 59
Andre Godin Interim President and Chief Executive Officer, Chief Financial Officer
Fotini Sampalis M.D., Ph.D. Chief Global Strategy Officer
Ronald Denis Director
Henri Harland Director
Harlan W. Waksal M.D. Director
Age: 60
Daniel Perry Independent Director
Reed V. Tuckson M.D. Independent Director